Hims & Hers Health, Inc. $HIMS Shares Purchased by Capital World Investors

Key Points

• Capital World Investors raised its stake by 1.2% to 18,783,194 shares—about 8.25% ownership—valued at roughly $1.065 billion at the end of the quarter.
• A settlement and commercial partnership with Novo Nordisk lets Hims & Hers offer FDA‑approved Wegovy/Ozempic (including pill formats), creating a potential high‑margin GLP‑1 revenue stream and triggering analyst upgrades.
• Hims & Hers beat Q4 EPS estimates ($0.08 vs. $0.02) but slightly missed revenue expectations, announced a $250 million buyback (~3% of shares), and remains exposed to volatility from high short interest and an ongoing securities‑style investigation.

Capital World Investors lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,783,194 shares of the company's stock after buying an additional 223,892 shares during the quarter. Capital World Investors owned about 8.25% of Hims & Hers Health worth $1,065,399,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Pinkerton Wealth LLC acquired a new stake in Hims & Hers Health during the 3rd quarter worth $208,000. Vestcor Inc raised its holdings in Hims & Hers Health by 68.2% during the third quarter. Vestcor Inc now owns 42,193 shares of the company's stock worth $2,393,000 after purchasing an additional 17,107 shares in the last quarter. Swiss National Bank lifted its position in Hims & Hers Health by 8.3% in the third quarter. Swiss National Bank now owns 376,000 shares of the company's stock valued at $21,327,000 after purchasing an additional 28,800 shares during the period. CreativeOne Wealth LLC lifted its position in Hims & Hers Health by 174.8% in the third quarter. CreativeOne Wealth LLC now owns 28,836 shares of the company's stock valued at $1,636,000 after purchasing an additional 18,341 shares during the period. Finally, Neo Ivy Capital Management boosted its holdings in Hims & Hers Health by 12.8% in the 3rd quarter. Neo Ivy Capital Management now owns 64,218 shares of the company's stock valued at $3,642,000 after purchasing an additional 7,273 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft increased their target price on Hims & Hers Health from $25.00 to $28.00 and gave the stock a "hold" rating in a research note on Tuesday. Evercore set a $24.00 price objective on Hims & Hers Health in a research report on Tuesday, February 24th. Zacks Research raised Hims & Hers Health from a "strong sell" rating to a "hold" rating in a report on Wednesday, February 25th. BTIG Research lowered shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $30.46.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $23.47 on Wednesday. The company has a market capitalization of $5.35 billion, a PE ratio of 46.01, a price-to-earnings-growth ratio of 4.24 and a beta of 2.55. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The business's 50-day moving average price is $24.31 and its 200 day moving average price is $37.75.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analysts' expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.11 earnings per share. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a stock buyback program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to repurchase up to 3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's management believes its stock is undervalued.

Insider Activity

In other news, COO Michael Chi sold 13,750 shares of the business's stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares of the company's stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 9,067 shares of the firm's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the transaction, the chief financial officer owned 91,617 shares in the company, valued at $2,779,659.78. This trade represents a 9.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 80,463 shares of company stock worth $2,846,696 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Settlement & commercial partnership with Novo Nordisk ends recent patent fight and lets HIMS offer FDA‑approved Wegovy/Ozempic (including new pill formats) on its platform — this materially reduces legal risk and opens a new, high‑margin revenue stream. Read More.
• Positive Sentiment: Multiple analyst upgrades and higher price targets followed the Novo news (Needham to Buy, Citi/Deutsche Bank raised targets/ratings), which supports further upside if GLP‑1 sales ramp. Read More.
• Positive Sentiment: HIMS is expanding its digital‑care platform (new specialties, lab testing, international moves) — a broader service set increases addressable market and cross‑sell opportunities for new branded drug offerings. Read More.
• Neutral Sentiment: Extremely high short interest and recent rapid gains raise the possibility of short‑squeeze‑driven volatility; that can amplify upside but also produce sharp reversals. Monitor short interest and volume closely. Read More.
• Neutral Sentiment: Recent Q4/FY results showed an EPS beat but a slight revenue miss — fundamentals show growth but remain mixed; GLP‑1 revenue could change near‑term guidance if rollout scales. Read More.
• Negative Sentiment: An asset manager has trimmed/left positions, signaling some institutional caution despite the deal — this could limit sustained buying if sentiment cools. Read More.
• Negative Sentiment: A securities‑style investigation into officers and directors was announced earlier this month — while the Novo settlement reduces one legal risk, governance/claims risk remains a headline risk for investors. Read More.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.